Deliver diagnostic confidence
Multiple guidelines, including NCCN, ASCO, EGAPP, and NICE,1-4 recommend universal screening of all newly diagnosed colorectal cancers for Lynch syndrome with the intent to prevent cancers and save lives.5 The VENTANA MMR IHC Panel class II IVD consists of VENTANA anti-MLH1 (M1), VENTANA anti-PMS2 (A16-4), VENTANA anti-MSH2 (G219-1129), VENTANA anti-MSH6 (SP93, and VENTANA BRAF V600E (VE1), and aids in identification of patients at risk for Lynch syndrome in patients diagnosed with colorectal cancer (CRC).
The inclusion of the exclusive VENTANA BRAF V600E (VE1) antibody helps refine the number of patients who receive additional testing for Lynch syndrome by aiding in the identification of sporadic CRC in the absence of MLH1 expression.6
The ready-to-use VENTANA MMR IHC Panel is optimized for use with the OptiView DAB IHC Detection Kit and ancillaries on the fully-automated BenchMark ULTRA instrument.